FGL
FGL: What We've Seen in Practice, and What the Research Says
FGL, short for Fibroblast Growth Loop, is a small peptide with an interesting design and an honest limitation, and we will put the limitation first. Almost everything known about FGL comes from laboratory and animal research. There are no human trials of it. So this page is written differently from most in our directory: it explains what FGL is and what the preclinical science shows, and it does not claim more than that.
FGL is a fifteen-amino-acid fragment copied from a protein your nervous system uses to help brain cells connect and repair, called the neural cell adhesion molecule, or NCAM. That fragment switches on a growth-factor receptor in the brain, which is where the "fibroblast growth" in its name comes from. In animals, that signal has been linked to memory, to the strengthening of connections between neurons, and to the protection of neurons under stress. Whether any of that carries over to people is exactly the question the research has not yet answered.
What we've seen in practice
FGL has real buzz in the cognitive and longevity world, so patients ask about it. Dr. Koniver starts in the same place every time: "Let me start with what we don't know."
The animal research, in his words, is fascinating. The human data does not exist. A peptide can be genuinely interesting at the level of the biology and still have nothing behind it in people, and that is FGL today: a compelling idea, a real preclinical record, and an empty human-evidence column.
FGL at a glance
A synthetic peptide of 15 amino acids, copied from the "FG loop" of the neural cell adhesion molecule (NCAM); it activates a growth-factor receptor involved in brain-cell connection and repair [1, 4]
.svg)
Memory and cognition, synaptic plasticity, neuroprotection (including against amyloid-beta), and neural repair, all in animal models [1, 2, 3]
.svg)
Preclinical only. Cell-culture and rodent studies plus reviews; no published human trials of any kind [1, 2, 3]
.svg)
Injection in the research literature
.svg)
Formula C71H116N20O25 · weight 1,649.8 g/mol · 15 amino acids (sequence EVYVVAENQQGKSKA) [4]
Not approved anywhere; a preclinical research peptide; prohibited in sport under WADA's non-approved-substances category
Dr. Koniver approaches FGL candor-first: the animal research is interesting, the human data does not exist yet. See what we've seen in practice above, and the regulatory status below
The fifteen-amino-acid sequence, in order (EVYVVAENQQGKSKA).
Where FGL comes from
Your brain is not a fixed wiring diagram. Neurons constantly form, strengthen, and prune their connections, and a family of proteins on the cell surface helps them do it. One of the most important is the neural cell adhesion molecule, NCAM, which helps neurons find and hold onto each other and, in doing so, supports learning, memory, and repair.
In the 1990s and 2000s, a group of Danish neuroscientists set out to capture NCAM's most useful signal in a single small molecule. They identified a specific loop on the NCAM protein, the FG loop, that activates the fibroblast growth factor receptor, one of the switches that tells a neuron to grow new connections and survive stress. They built a fifteen-amino-acid peptide reproducing that loop and called it FGL. The idea was elegant: deliver NCAM's growth-and-repair signal without the whole protein. What followed was two decades of animal research exploring that idea, and, so far, no human trials to test whether it works in people.
How FGL works
.svg)
FGL reproduces the FG loop of NCAM and uses it to activate the fibroblast growth factor receptor on neurons. That receptor drives the outgrowth of new neural connections and supports neuron survival. [1, 2]
.svg)
In animal preparations, FGL facilitates long-term potentiation, the strengthening of synapses that underlies learning and memory. In rats it promoted the formation of new synapses and helped consolidate memories. [1]
.svg)
In rodent models, FGL protected neurons against damage from amyloid-beta, the protein fragment associated with Alzheimer's pathology, and reduced markers of neuroinflammation. These are animal findings, and we present them as such. [2]
An interesting preclinical record, an empty human-evidence column [1, 4]
What the research shows
Here is the whole picture, told plainly. FGL has a genuinely interesting body of preclinical research behind it, and no human research at all.
In animals, mostly rats, FGL has repeatedly done what its design predicts. It facilitated long-term potentiation, promoted new synapse formation, aided memory consolidation, and protected hippocampal neurons against amyloid-beta toxicity across multiple studies, beginning with the foundational 2004 work and continuing through a series of neuroprotection and plasticity experiments. Reviews of cognitive-enhancing and NCAM-mimetic peptides consistently include FGL as a promising candidate. [1, 2, 3]
Now the part the reference material we started from obscured, and we will not. None of this is human data. There are no published human trials of FGL, not for cognition, not for neuroprotection, not for safety. Every efficacy finding above comes from a cell culture or an animal. That does not make FGL uninteresting, animal neuroscience is how most good ideas begin, but it does mean the honest description of FGL is "a peptide with encouraging preclinical results and an empty human-evidence column," and anyone describing it as a demonstrated cognitive enhancer for people is well ahead of the science.
Memory and synaptic plasticity
Rodent studies (from Cambon 2004 onward)
Facilitated long-term potentiation; promoted synaptogenesis; aided memory consolidation
Animal only; no human data [1]
Neuroprotection
Amyloid-beta rodent models (Corbett and others)
Protected hippocampal neurons against amyloid-beta toxicity
Animal only; human trials needed [2, 3]
Neural repair
Injury / regeneration models
Promoted neurite outgrowth and axonal regrowth
Animal only [2]
Cognitive-enhancer reviews
Literature reviews (Asua and others)
List FGL as a promising candidate
Reviews of preclinical data, not new human evidence
The evidence, area by area
Tiers on this page: Animal research only · No human trials.
Because there are no human trials, there is no human safety data for FGL. What exists is preclinical: animal studies reported good tolerability and no obvious organ toxicity at the doses studied. That is reassuring as far as it goes, and it does not go as far as a first-in-human safety study, which has never been done.
Two cautions carry over sensibly from the biology. Because FGL acts on synaptic plasticity and excitability, there is a theoretical reason for caution in anyone with a seizure disorder. And, as with any peptide, pregnancy and breastfeeding are exclusions where no safety data exists. The broader point is the honest one: a compound with no human safety record is, by definition, not something to approach casually, and certainly not to self-source from unregulated "research chemical" suppliers of unknown purity.
Regulatory status
The following is descriptive, not advice. Regulatory status changes; the date below is when we last checked.
FGL has not been part of the FDA's compounding-nomination process; there is no Category 2 history and it was not among the peptides the FDA advisory committee considered in 2024 or 2026.
As a medicine, worldwide
Not an approved medicine anywhere. A preclinical research peptide, studied in animals, with no regulatory approval anywhere. [1]
In competitive sport
Prohibited
As a non-approved substance, FGL falls under WADA's S0 category (non-approved substances), prohibited at all times, in and out of competition.[5]
Everywhere else,
in general
No national health authority has approved FGL for medical use. Availability and rules vary by country, and products offered outside regulated channels carry real quality risks.
Regulatory information current as of 12 August 2026.
FGL, answered plainly
It is a synthetic peptide of fifteen amino acids, copied from a loop on the neural cell adhesion molecule (NCAM), a protein your brain uses to help neurons connect and repair. FGL activates a growth-factor receptor involved in that process. It has been studied in animals for memory, synaptic plasticity, and neuroprotection.
We do not know, because it has never been tested in people. From the research In animals it improved memory-related measures and strengthened synaptic connections. There are no human trials, so any claim about cognitive benefit in people is ahead of the evidence. [1]
There is no human safety data. Animal studies reported good tolerability, but a first-in-human safety trial has never been done. There is a theoretical reason for caution in people with seizure disorders, and unregulated product quality is a separate, real risk.
Candor first. As he puts it, "let me start with what we don't know." He describes FGL accurately, a fragment of the neural cell adhesion molecule that helps brain cells communicate and repair, calls the animal research fascinating, and is clear that the human data does not exist yet. FGL gets the same evidence standard as everything else we do, which for now means an honest account rather than a recommendation.
No. As an unapproved substance it is prohibited at all times. The regulatory status section above has the specifics. [5]
Related in this directory
References
- Cambon K, et al. A synthetic neural cell adhesion molecule mimetic peptide promotes synaptogenesis, enhances presynaptic function, and facilitates memory consolidation. Journal of Neuroscience. 2004;24(17):4197-4204. (Rat study.)
- Berezin V, Bock E, et al. NCAM-derived FG loop peptide (FGL) and fibroblast growth factor receptor activation: neurite outgrowth, synaptic plasticity, and neuroprotection. Preclinical program literature.
- Corbett and colleagues. FGL protection against amyloid-beta-induced hippocampal neuron loss (rodent models). Preclinical.
- PubChem. FGL peptide (CID 16200289): molecular formula, weight, and sequence.
- WADA. The Prohibited List, S0 (non-approved substances, prohibited at all times).
- Koniver Method - Dr. Koniver's clinical-experience section for FGL is in preparation and will be added after review.
This page is for informational and educational purposes and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for consultation with a qualified healthcare provider. FGL is not approved by the FDA or any national health authority for therapeutic use, has not been tested in human trials, and is prohibited in competitive sport. Statements describing how Dr. Koniver and the Koniver Wellness team discuss and approach FGL reflect their clinical judgment and reading of the evidence, which is not the same as controlled clinical evidence, and this page describes no human use of FGL. Regulatory information on this page is provided for general awareness, is current as of the date shown, and may have changed; verify with official sources or a licensed practitioner in your jurisdiction before making any decision. Koniver Wellness serves a worldwide readership: the availability and regulatory status of the therapies discussed vary by country and region, so please check the laws and regulations of your own jurisdiction and consult a licensed local practitioner before pursuing any therapy. Therapies described on this site are prescribed and supervised by licensed physicians for Koniver Wellness patients. Use of this site does not create a physician-patient relationship.
INTERESTED IN PEPTIDES?
START WITH THE RIGHT QUESTIONS.
Understand what peptides can and cannot do, what the evidence actually says, and whether physician-guided peptide therapy makes sense for you.